Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site
Meets the growing demand for U.S.-based contract development and manufacturing organizations (CDMOs) Further improves capabilities to handle increasing complexity of active pharmaceutical ingredients (APIs) Important step in Evonik's asset balancing strategy by investing in Next...
Meets the growing demand for U.S.-based contract development and manufacturing organizations (CDMOs) Further improves capabilities to handle increasing complexity of active pharmaceutical ingredients (APIs) Important step in Evonik's asset balancing strategy by investing in Next...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.